（文章来源：上海证券报） 人民财讯11月14日电，11月13日晚，随着中芯国际、诺诚健华2家多地上市的红筹公司完成三季报披 露，科创板592家公司的"成绩单"全部出炉。前三季度，面对复杂的外部环境，科创板公司整体业绩重 拾升势，单季度净利润同比大幅增长75%。"硬科技"企业研发投入持续加码，集成电路、人工智能、生 物医药等重点产业加速培育新质生产力，为"十五五"时期实现高水平科技自立自强破局开路、筑牢根 基。 ...

Core Viewpoint - The company, Nocare Biopharma, reported significant growth in revenue and improvements in gross margin for the first nine months of 2025, driven by the sales of its core product, Obatuzumab, and a licensing agreement with Prolium Bioscience Inc [2][3]. Financial Performance - Total revenue for the first nine months of 2025 reached 1.115 billion RMB, representing a year-on-year increase of 59.85% [2]. - The gross margin improved to 88.8%, up from 86.0% in the same period last year, an increase of 2.8 percentage points [2]. - The net loss for the same period was 72 million RMB, a reduction of 74.78% compared to the previous year [2]. Product Performance - Sales revenue from the core product, Obatuzumab, amounted to 1.010 billion RMB in the first nine months of 2025, marking a year-on-year growth of 45.77% [3]. - In April 2025, Obatuzumab received approval for a new indication for first-line treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in adult patients [3]. - Obatuzumab is the first and only BTK inhibitor approved in China for the MZL indication and has been included in multiple recommendations in the latest CSCO lymphoma treatment guidelines [3]. Cash Position - As of September 30, 2025, the company held approximately 7.759 billion RMB in cash and cash equivalents, which supports the acceleration of its pipeline projects [4].

Group 1 - Shimai Pharmaceutical plans to list on the Hong Kong Stock Exchange, having submitted its application with Huatai International as the sole sponsor [1] - Established in 2017, Shimai is a pioneer in next-generation T-cell engagers (TCE) aimed at utilizing the human immune system to combat cancer, with four self-developed clinical-stage candidates [1] - The company's core technology, the masking TCE, is designed for selective activation in tumors, focusing on solid tumors, which aligns with the growth trend in the TCE sector [1] Group 2 - Gilead Sciences announced the entry of its new generation of drugs ASC36 and ASC35 into clinical development, targeting obesity with a planned FDA submission in Q2 2026 [2] - ASC36 and ASC35 are proprietary long-acting combination formulations with superior physicochemical stability, designed to avoid aggregation and precipitation [2] - ASC36 is positioned as a cornerstone therapy for treating metabolic diseases, potentially offering better efficacy and tolerability compared to GLP-1 therapies [2] Group 3 - InnoCare Pharma's new drug DB-1418 has been approved for clinical trials in China, targeting advanced/metastatic solid tumors as an EGFR/HER3 bispecific antibody-drug conjugate (ADC) [3] - The approval of DB-1418 aims to address treatment bottlenecks in resistant solid tumors, enhancing the company's pipeline competitiveness [3] Group 4 - InnoCare Pharma reported a nearly 60% increase in total revenue for the first three quarters of 2025, reaching 1.12 billion yuan, driven by the sales growth of its core product, BTK inhibitor Orelabrutinib [4] - Orelabrutinib's revenue increased by 45.8% year-on-year, surpassing last year's total revenue, while the company's losses narrowed by 74.8% to 70 million yuan [4] - The revenue growth and reduced losses indicate a potential profitability turning point, which may accelerate the advancement of the innovation pipeline and strengthen the company's position in the BTK field [4]

Core Viewpoint - The company, Innovent Biologics, reported significant growth in revenue and improved gross margin for the first nine months of 2025, driven by the sales of its core product, Ibrutinib (Yinokai), and a licensing agreement with Prolium Bioscience Inc. [3][4] Financial Performance - Total revenue for the first nine months of 2025 reached 1.115 billion yuan, a year-on-year increase of 59.85% [3] - Gross margin improved to 88.8%, up from 86.0% in the same period last year, reflecting a 2.8 percentage point increase [3] - The net loss for the same period was 72 million yuan, a reduction of 74.78% compared to the previous year [3] Product Performance - Sales revenue from Ibrutinib (Yinokai) for the first nine months of 2025 was 1.010 billion yuan, representing a year-on-year growth of 45.77% [4] - In April 2025, Ibrutinib received approval for a new indication for first-line treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in adult patients [4] - Ibrutinib is the first and only BTK inhibitor approved in China for the MZL indication and is included in multiple recommendations in the latest CSCO lymphoma treatment guidelines [4] Cash Position - As of September 30, 2025, the company held approximately 7.759 billion yuan in cash and cash equivalents, enabling it to accelerate the development of its pipeline projects [5] Shareholder Information - As of the reporting period, the total number of shares issued by the company was 1,764,643,952, with 84.79% listed in Hong Kong and 15.21% on the Shanghai Stock Exchange [6][7]

Core Insights - The overall performance of companies listed on the Sci-Tech Innovation Board (STAR Market) has shown a strong rebound in the first three quarters, with a significant year-on-year net profit growth of 75% in Q3 [2] - The focus on "hard technology" has led to increased R&D investments, particularly in key industries such as integrated circuits, artificial intelligence, and biomedicine, contributing to the foundation for high-level technological self-reliance [2] Performance Overview - In the first three quarters, STAR Market companies achieved a total revenue of 1.11 trillion yuan, a year-on-year increase of 7.9%, and a net profit of 49.268 billion yuan, up 8.9% [2] - Excluding four leading photovoltaic companies, overall revenue and net profit growth rates were 14.6% and 30.6%, respectively, indicating an amplified growth momentum [2] - Over 70% of companies reported revenue growth, and nearly 60% saw net profit increases, with 158 companies experiencing net profit growth exceeding 50% [2] Industry Highlights - The STAR Market's top enterprises and growth-oriented companies complement each other well, with the Sci-Tech 50 Index companies accounting for 46% of revenue and 50% of net profit [3] - The Sci-Tech 100 Index companies demonstrated high growth elasticity, with revenue and net profit increasing by 12% and 134%, respectively, becoming the "vanguard" of performance growth [3] R&D Investment - Total R&D investment by STAR Market companies reached 119.745 billion yuan, 2.4 times the net profit, with a median R&D intensity of 12.4%, leading A-share sectors [4] - The biomedicine sector saw revenue growth of 11% and net profit growth of 48%, driven by the rapid commercialization of innovative drugs [4] - Nine first-class new drugs were approved for market entry during the reporting period, with significant international business development transactions totaling over 13 billion USD [4] Growth of Emerging Companies - 35 unprofitable companies in the Sci-Tech Growth Layer reported a revenue increase of 39% and a significant reduction in net losses by 65% [5] - These companies are focusing on R&D with a median R&D intensity of 44.3%, indicating a promising development trend [5] Competitive Advantages in Key Industries - The integrated circuit industry, crucial for technological self-reliance, saw 121 related companies achieve a revenue growth of 25% and a net profit growth of 67% [6] - Major players like SMIC and Huahong Semiconductor maintained high capacity utilization rates, with record sales revenue [6] - The AI industry has emerged as a new growth pillar, with significant revenue increases across the supply chain, particularly in computing and data transmission sectors [7] Renewable Energy Sector - In the photovoltaic sector, 17 related companies significantly reduced their net losses by 28% [7] - The lithium battery industry experienced a revenue growth of 7% and a net profit of 1.02 billion yuan, marking a return to profitability [7]

Core Viewpoint - 诺诚健华 reported a revenue of 383.94 million yuan for Q3 2025, marking a year-on-year increase of 38.09%, but incurred a net loss of 34.32 million yuan [1][4] Financial Performance - Revenue for Q3 2025 was 383.89 million yuan, up 38.09% year-on-year, while total revenue for the first nine months reached 1.11 billion yuan, a 59.85% increase [3][4] - The company reported a net loss of 34.32 million yuan for Q3 2025, with a net loss of 72 million yuan for the first nine months, a 74.78% reduction compared to the previous year [4][6] - Gross margin improved to 88.8%, up from 86.0% year-on-year [3] Product Performance - The growth in revenue is primarily attributed to the sales of the core product, Acalabrutinib, which generated 1.01 billion yuan in sales for the first nine months, a 45.77% increase [4][7] - Acalabrutinib has been approved for four hematological indications in China and is the first BTK inhibitor approved for relapsed/refractory marginal zone lymphoma [4][5] Market Dynamics - Acalabrutinib's sales are expected to continue growing, with projected revenues of 2.41 billion yuan in 2021, 5.66 billion yuan in 2022, 6.71 billion yuan in 2023, and 10 billion yuan in 2024 [7] - The domestic BTK inhibitor market is becoming increasingly competitive, with five approved products, including Acalabrutinib and others from major pharmaceutical companies [8] - The patent for Ibrutinib, a competing product, will expire in December 2026, potentially leading to an influx of generic versions and intensifying market competition [8] Research and Development - R&D expenses totaled 226.35 million yuan in Q3 2025, accounting for 58.96% of revenue, a decrease from the previous year [3][4] - The company is expanding Acalabrutinib's indications, with ongoing clinical trials for multiple sclerosis and immune thrombocytopenic purpura [7][8]

Core Insights - The overall performance of companies on the Sci-Tech Innovation Board (STAR Market) has shown a significant recovery, with a 75% year-on-year increase in net profit for the third quarter [2][4] - The board's companies achieved approximately 1.1 trillion yuan in revenue for the first three quarters of 2025, marking a 7.9% year-on-year growth, and a net profit of 492.68 billion yuan, up 8.9% [2][4] - The focus on "hard technology" sectors such as integrated circuits, artificial intelligence, and biomedicine is fostering new productive forces and supporting high-level technological self-reliance [1][4] Financial Performance - In the first three quarters, over 70% of companies reported revenue growth, and nearly 60% saw an increase in net profit, with 158 companies experiencing net profit growth exceeding 50% [2][4] - The STAR Market's R&D investment totaled 1,197.45 billion yuan, which is 2.4 times the net profit, with a median R&D intensity of 12.4%, leading the A-share market [2][4] Sector Highlights - The integrated circuit industry reported a 25% year-on-year revenue growth and a 67% increase in net profit, with major players like SMIC and Hua Hong Semiconductor achieving record sales [4][5] - The artificial intelligence sector has emerged as a new growth pillar, with companies like Cambricon and Haiguang Information seeing revenue increases of nearly 24 times and 55%, respectively [5][6] - The biopharmaceutical industry experienced an 11% revenue growth and a 48% increase in net profit, with significant advancements in new drug approvals and international transactions [6][7] Growth Potential - The STAR Market's "1+6" reform has effectively supported unprofitable tech companies, with 35 companies in the growth tier showing a 39% revenue increase and a 65% reduction in net profit losses [3][4] - The renewable energy sector is stabilizing, with solar companies reducing losses significantly and lithium battery companies reporting a 7% revenue growth in the third quarter [6][7]

Group 1: Overall Performance of Sci-Tech Innovation Board Companies - In the first three quarters, Sci-Tech Innovation Board companies achieved operating revenue of 1.105 trillion yuan, a year-on-year increase of 7.9% [1] - Net profit reached 49.268 billion yuan, growing by 8.9% year-on-year, with a significant 75% increase in net profit for the third quarter alone [1] - Over 70% of companies reported revenue growth, and nearly 60% saw net profit growth, with 158 companies experiencing net profit increases exceeding 50% [1] Group 2: R&D Investment and Industry Performance - The total R&D investment for the Sci-Tech Innovation Board in the first three quarters was 119.745 billion yuan, 2.4 times the net profit, with a median R&D intensity of 12.4% [2] - The integrated circuit industry showed strong performance, with 121 related companies achieving a 25% year-on-year revenue increase and a 67% rise in net profit [2] - The artificial intelligence industry emerged as a new growth driver, with significant revenue increases in computing power and related sectors [2] Group 3: Sector-Specific Insights - The biopharmaceutical industry saw an 11% increase in revenue and a 48% rise in net profit, driven by the approval of new drugs and international business development [3] - The renewable energy sector is experiencing a reduction in losses, particularly in the photovoltaic field, with some companies turning profitable [3] - The lithium battery industry is witnessing a recovery in demand and prices, with 19 related companies reporting a 7% increase in revenue and a return to profitability [3]

Core Insights - The overall performance of the Sci-Tech Innovation Board (STAR Market) has shown a significant recovery, with a 75% year-on-year increase in net profit for the third quarter [1][2] - The board's companies achieved a total operating revenue of 1,105.01 billion yuan, representing a 7.9% year-on-year growth, and a net profit of 49.27 billion yuan, up 8.9% year-on-year [1][2] Performance Distribution - Over 70% of companies on the STAR Market reported revenue growth, and nearly 60% saw an increase in net profit; 158 companies had net profit growth exceeding 50%, while 46 companies turned losses into profits [2] - The Sci-Tech 50 Index companies accounted for 46% of total revenue and 50% of net profit, serving as a stabilizing force for the board [2] - The Sci-Tech 100 Index companies exhibited high growth elasticity, with revenue and net profit increasing by 12% and 134% year-on-year, respectively [2] Innovation and R&D Investment - The total R&D investment for the STAR Market reached 119.75 billion yuan, which is 2.4 times the net profit, with a median R&D intensity of 12.4%, leading all A-share sectors [2] - The "1+6" reform initiated in June aims to support unprofitable tech companies, with 35 such companies showing promising growth; their revenue increased by 39% year-on-year, while net profit losses were reduced by 65% [2] - Leading companies are demonstrating potential for profitability, with Cambrian Technology achieving profitability for four consecutive quarters and BeiGene's quarterly revenue surpassing 10 billion yuan [2] Future Outlook - The STAR Market is expected to attract and nurture more world-class technology enterprises, with a focus on innovation as a key driver for economic growth [3]

Core Viewpoint - Nuo Cheng Jian Hua is optimistic about its future development, expecting to achieve breakeven in 2025, two years ahead of its profitability target, supported by strong revenue growth and a significant licensing deal with Zenas [1][2]. Financial Performance - The company reported a 59.8% year-on-year increase in total revenue for the first three quarters of 2025, reaching 1.12 billion yuan, primarily driven by the sales of its core product, the BTK inhibitor Aobutini [1]. - Aobutini's revenue for the same period rose by 45.8% to 1.01 billion yuan, surpassing last year's total revenue [1]. - The company's losses narrowed significantly by 74.8%, down to 70 million yuan, due to rapid revenue growth and improved cost efficiency [1]. Strategic Partnerships - The licensing agreement with Zenas, valued at over 2 billion USD, is expected to enhance Nuo Cheng Jian Hua's financial performance and support its global expansion efforts [2][3]. - Zenas is advancing global Phase III clinical trials for Aobutini targeting primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS) patients, with trials set to start in Q1 2026 [2]. Product Pipeline and Market Potential - Nuo Cheng Jian Hua is focusing on three key therapeutic targets: BTK, CD19, and BCL2, to strengthen its position in the hematological oncology market [4]. - The CD19 monoclonal antibody, Tanshizhuo, has been commercially launched in China, filling a gap in the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) [5]. - The BCL2 inhibitor, Mesutoclax, is undergoing multiple clinical trials, showing promise in treating various hematological malignancies [6][7]. Expansion into Autoimmune Diseases - The global market for autoimmune diseases is projected to reach 185 billion USD by 2029, with Nuo Cheng Jian Hua actively advancing multiple Phase III clinical trials for its pipeline products [8]. - Aobutini is the first BTK inhibitor to show efficacy in systemic lupus erythematosus (SLE) in Phase II trials, with data expected to be released in Q4 2025 [8]. Research and Development - The company has increased its R&D expenditure by 9.9% year-on-year to 680 million yuan, with plans to submit 5 to 7 clinical trial applications for new drug candidates by 2026 [10][11]. - Nuo Cheng Jian Hua is developing a new ADC drug, ICP-B794, which has completed its first patient dosing, and aims to leverage its ADC platform for further innovations [10][11].